Compounded GLP-1s set to exit market, ending your ability to prescribe
The brisk online market in compounded versions of GLP-1s — less expensive than the first-line, on-patent versions such as Ozempic — are about to lose their FDA shortage authorization. Know the deadlines, which would end your ability to prescribe them.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.
Quick, Current, Complete - www.findacode.com